Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Slamon, D.J. ; Neven, P. ; Chia, S. ; Jerusalem, G. ; De Laurentiis, M. ; Im, S. ; Petrakova, K. ; Valeria Bianchi, G. ; Martín, M. ; Nusch, A. ; Sonke, G.S. ; De la Cruz-Merino, L. ; Beck, J.T. ; Ji, Y. ; Wang, C. ; Deore, U. ; Chakravartty, A. ; Zarate, J.P. ; Taran, T. ; Fasching, P.A.

Annals of oncology, 2021-08, Vol.32 (8), p.1015-1024 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível